Quantcast
Last updated on April 21, 2014 at 10:27 EDT

Latest Flecainide Stories

2013-10-28 12:25:16

NASDAQ: CRME TSX: COM VANCOUVER, Oct. 28, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced that the abstract, Conversion of Acute Atrial Fibrillation with Propafenone or Vernakalant, is being presented as an oral presentation by Dr. Diego Conde, Chief of Cardiovascular Emergency Care Section, Instituto Cardiovascular de Buenos Aires, at the Venice Arrhythmias meeting, being held in Venice, Italy, October 27-29, 2013. This abstract is competing...

2013-09-23 08:28:52

NASDAQ: CRME   TSX: COM VANCOUVER, Sept. 23, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced publication of positive data from an open label study in patients with atrial fibrillation that compared treatment with vernakalant intravenous (IV) to oral propafenone and oral flecainide. Patients treated with vernakalant achieved conversion to normal sinus rhythm in a median time of 12 minutes compared to 151 minutes for the propafenone group and...

2012-11-28 13:14:15

Digoxin, a drug that has been used worldwide for centuries to treat heart disease, is associated with a significant increase in deaths in patients with atrial fibrillation (AF), according to results from a study published online today (Wednesday) in the European Heart Journal. Digoxin is extracted from the foxglove plant (digitalis) and it helps the heart beat more strongly and with a more regular rhythm. It is commonly used in AF patients, and also in patients with heart failure. However,...

2012-06-18 13:29:50

Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF. In most cases, AF can be treated successfully by an electrical cardioversion. Unfortunately, in the majority of patients, AF recurs during the first days or weeks after cardioversion. This is due to...

2011-08-31 23:35:05

Computer-based simulations solve decades-old mystery of failed anti-arrhythmia therapy UC Davis researchers have developed an accurate computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients. The new tool -- described in the Aug. 31 issue of the journal Science Translational Medicine -- will help scientists screen anti-arrhythmia medications early in the drug-development pipeline and eventually guide physicians in...

2011-08-29 20:13:07

However, the general health benefits from physical exercise outweigh the increased risk of this heart rhythm disorder A Norwegian survey carried out between 1974 and 2003 showed that there was a graded independent increase in the risk of AF with increasing levels of physical activity in a population-based study among men with ostensibly no other heart disease. In women the data were inconclusive. Speaking at a press conference at the ESC Congress in Paris today, Prof Knut Gjesdal from...

2009-04-02 12:18:12

New research has found that the answer to treating a rare inherited heart disorder could lie with a drug already on the market. Associate Professor Derek Laver from the University of Newcastle and international colleagues have found that Flecainide "“ a drug used to treat heart arrhythmias "“ could also be used to treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CVPT is a heart arrhythmia induced by emotional stress or exercise. It is estimated to...